DIA/FDA Oligonucleotide-based Therapeutics Conference

Peter S. Miele, MD

Medical Officer, Division of Antiviral Products, OND, OMPT, OAP, CDER

James D. Thompson, PhD

Vice President, Pharmaceutical Development

Phase 2 Data on ALN-RSV01 for the Treatment of Bronchiolitis Obliterans Syndrome in RSV-infected Lung Transplant Patients

Jared A. Gollob, MD

Alnylam Pharmaceuticals, Inc., United States

Vice President, Clinical Research

Ebola

Ian MacLachlan, PhD

Tekmira Pharmaceuticals Corporation, Canada

Executive Vice President and Chief Scientific Officer

iCo-007 in Treatment of Diabetic Macular Edema

Peter Hnik, MD

iCo Therapeutics, Inc., Canada

Chief Medical Officer